


PE
4/1/02



Form 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of April

PROCESSED

APR 15 2002

THOMSON
FINANCIAL

.....Teva Pharmaceutical Industries Limited.....
(Translation of registrant's name into English)

.....5 Basel Street, P.O. Box 3190.....
.....Petach Tikva 49131, Israel.....
(Address of principal executive offices)



Teva Pharmaceutical Industries Ltd.

Web Site: www.tevapharm.com

Contact: Dan Suesskind

Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

Eli Shohet

VP - Business Development
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7463

FOR IMMEDIATE RELEASE

Dorit Meltzer

Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554

TEVA ANNOUNCES AGREEMENT TO ACQUIRE BAYER FRANCE GENERIC OPERATIONS

Jerusalem, Israel, April 4, 2002 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today, further to the release dated February 5, 2002, that it has reached an agreement with Bayer Pharma S.A. to acquire Bayer Classics S.A., its French generic pharmaceutical marketing company and related manufacturing facility for a purchase price of €97 million. Bayer Classics S.A. is the third largest supplier of generic pharmaceuticals to the French retail market. The transaction is expected to be completed during the second quarter of 2002.

Israel Makov, Teva's Chief Operating Officer, stated, "This acquisition will enable Teva to become a major player in the fast growing emerging generic pharmaceutical market in France further enhancing our leading position in Europe."

Teva, through the combination of its existing operations in France and the operations of Bayer Classics S.A. will offer the French market 72 generic products (in 153 presentations) and will have 49 products in the pipeline of pending generic product registrations. For the last six months ending March 31, 2002, Bayer Classics had revenues exceeding €26 million.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the timing of obtaining the necessary regulatory approvals and satisfying the other conditions under the agreement with Bayer Pharma, the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on a strategy of acquiring companies and on strategic alliances, exposure to product liability claims, dependence on patent and other protections for our innovative products, fluctuations in currency, exchange and interest rates, operating results, and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

Teva Pharmaceutical
Industries Limited

.....
(Registrant)

By:


Dan Suesskind
Chief Financial Officer

Date: April 5, 2002
.....